000301763 001__ 301763
000301763 005__ 20250828084755.0
000301763 0247_ $$2doi$$a10.1016/j.eururo.2025.05.020
000301763 0247_ $$2pmid$$apmid:40461322
000301763 0247_ $$2ISSN$$a0302-2838
000301763 0247_ $$2ISSN$$a1421-993X
000301763 0247_ $$2ISSN$$a1873-7560
000301763 0247_ $$2altmetric$$aaltmetric:177837077
000301763 037__ $$aDKFZ-2025-01143
000301763 041__ $$aEnglish
000301763 082__ $$a610
000301763 1001_ $$0P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aAl-Monajjed, Rouvier$$b0$$eFirst author$$udkfz
000301763 245__ $$aProstate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging-targeted Biopsy in the PROBASE Trial.
000301763 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000301763 3367_ $$2DRIVER$$aarticle
000301763 3367_ $$2DataCite$$aOutput Types/Journal article
000301763 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756363611_18474
000301763 3367_ $$2BibTeX$$aARTICLE
000301763 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301763 3367_ $$00$$2EndNote$$aJournal Article
000301763 500__ $$a#EA:C130#LA:C130# / 2025 Sep;88(3):240-244
000301763 520__ $$aThe optimal approach for prostate cancer (PC) screening, including the ideal starting age and most effective diagnostic method, remains under investigation. We evaluated the diagnostic performance of magnetic resonance imaging (MRI)-targeted biopsy (TBx) and systematic biopsy (SBx) in detecting clinically significant PC (csPC) in men aged 45-50 yr in PROBASE, a prospective, randomized trial of a risk-adapted screening strategy. A total of 525 participants with elevated prostate-specific antigen (≥3 ng/ml) underwent MRI followed by biopsy. Of the 209 PC cases detected, 148 (71%) were csPC. SBx identified 94% of csPC cases, while TBx detected 74% (p ≤ 0.05). SBx also diagnosed significantly more low-grade PCs than TBx (p < 0.001). These findings suggest that relying solely on MRI-TBx may lead to underdiagnosis of csPC. Combining SBx with TBx remains the most effective strategy for early detection of PC in young men undergoing screening. Future research should explore optimization strategies to reduce unnecessary biopsies while maintaining high detection rates for csPC. This trial is registered on the ISRCTN registry as ISRCTN37591328 (https://www.isrctn.com/ISRCTN37591328). The study protocol can be accessed at https://doi.org/10.1016/j.eururo.2013.05.022.
000301763 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000301763 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301763 650_7 $$2Other$$aFusion biopsy
000301763 650_7 $$2Other$$aMagnetic resonance imaging
000301763 650_7 $$2Other$$aProstate cancer
000301763 650_7 $$2Other$$aProstate-specific antigen
000301763 650_7 $$2Other$$aRisk-adapted screening
000301763 650_7 $$2Other$$aUltrasound
000301763 7001_ $$aBoschheidgen, Matthias$$b1
000301763 7001_ $$aLakes, Jale$$b2
000301763 7001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b3$$udkfz
000301763 7001_ $$aRadtke, Jan-Philipp$$b4
000301763 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b5$$udkfz
000301763 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b6$$udkfz
000301763 7001_ $$aHerkommer, Kathleen$$b7
000301763 7001_ $$aJahnen, Matthias$$b8
000301763 7001_ $$aGschwend, Jürgen E$$b9
000301763 7001_ $$aDüx, Daniel$$b10
000301763 7001_ $$aWacker, Frank$$b11
000301763 7001_ $$aMakowski, Marcus R$$b12
000301763 7001_ $$aSauter, Andreas$$b13
000301763 7001_ $$aKuczyk, Markus A$$b14
000301763 7001_ $$aHarke, Nina$$b15
000301763 7001_ $$aDebus, Jürgen$$b16
000301763 7001_ $$aGrott, Christoph$$b17
000301763 7001_ $$aArsov, Christian$$b18
000301763 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b19$$udkfz
000301763 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris$$b20
000301763 7001_ $$aGiesel, Frederik$$b21
000301763 7001_ $$aKristiansen, Glenn$$b22
000301763 7001_ $$aAntoch, Gerald$$b23
000301763 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b24$$udkfz
000301763 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b25$$udkfz
000301763 7001_ $$aSchimmöller, Lars$$b26
000301763 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b27$$eLast author$$udkfz
000301763 773__ $$0PERI:(DE-600)1482253-2$$a10.1016/j.eururo.2025.05.020$$gp. S0302283825002982$$n3$$p240-244$$tEuropean urology$$v88$$x0302-2838$$y2025
000301763 909CO $$ooai:inrepo02.dkfz.de:301763$$pVDB
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000301763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000301763 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000301763 9141_ $$y2025
000301763 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-20$$wger
000301763 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL : 2022$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000301763 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bEUR UROL : 2022$$d2024-12-20
000301763 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000301763 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000301763 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000301763 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x2
000301763 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x3
000301763 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000301763 980__ $$ajournal
000301763 980__ $$aVDB
000301763 980__ $$aI:(DE-He78)C130-20160331
000301763 980__ $$aI:(DE-He78)E010-20160331
000301763 980__ $$aI:(DE-He78)ED01-20160331
000301763 980__ $$aI:(DE-He78)C020-20160331
000301763 980__ $$aUNRESTRICTED